Article Text


Prescribing trends in asthma: a longitudinal observational study
  1. S Turner1,
  2. M Thomas2,
  3. J von Ziegenweidt3,
  4. D Price2,3
  1. 1
    Department of Child Health, University of Aberdeen, Aberdeen, Scotland, UK
  2. 2
    Department of General Practice and Primary Care, University of Aberdeen, Aberdeen, Scotland, UK
  3. 3
    Respiratory Research Limited, Sankence, Norfolk
  1. Dr S Turner, Department of Child Health, Royal Aberdeen Children’s Hospital, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK; s.w.turner{at}


Background: Inhaled corticosteroids (ICS) are effective treatment for childhood asthma. Cross-sectional studies indicate that some asthmatic children are treated with excessively high doses of ICS and are at risk of serious adverse effects.

Objective: To describe longitudinal trends in asthma prescribing for children, with particular reference to very-high-dose (unlicensed) ICS prescribing.

Design: Retrospective, cross-sectional, observational study of general practitioner prescribing for asthma drugs in children aged under 12 years with a recorded asthma diagnosis between 1992 and 2004 using the General Practice Research Database (GPRD).

Results: Data were available for an average of 357 956 children per year. The percentage of children prescribed ICS increased from 2.7 in 1992 to 7.0 in 1997 and 1998 and then fell to 3.3 in 2004. In children under 5 years with asthma, very-high-dose ICS prescriptions (>400 μg/day) fell from 10.6% of all ICS prescriptions in 1992 to 4.5% by 2004. In contrast, very-high-dose ICS prescriptions (>800 μg/day) for asthmatic children aged 5–11 years rose from 1.1% in 1992 to 4.6% in 2004. Oral corticosteroid prescribing in under 5-year-olds who had been prescribed ICS fell from 37.1% in 1992 to 21.7% 1999 and remained constant thereafter; the respective percentages for those aged 5–11 years olds were 20.1 and 12.4.

Conclusions: Trends for corticosteroid prescribing in childhood asthma changed dramatically between 1992 and 2004. There are several plausible reasons for this.

View Full Text

Statistics from

Supplementary materials


  • Additional data are published online only at

  • Funding: Respiratory Research Limited provided funding for the database analyses reported here. Access to the GPRD database was provided by a grant from Schering Plough Ltd.

  • Competing interests: None.

  • Ethics approval: Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Atoms
    Howard Bauchner